Drug Trial Radar · NCT05028946
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 1, 2022
Primary completion
Jul 7, 2023
Study completion Nov 7, 2023
Sponsor
- Lead sponsor
- Tiziana Life Sciences LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to establish the safety and tolerability of multiple ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily for 5 days per week over 2 weeks in participants with moderate to severely active Crohn's Disease (CD).
Conditions
- Crohn's Disease
Interventions
ForalumabDrug
Foralumab will be administered per dose and schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.